Drug intelligence / Profile preview

PF-3864086

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-3864086 is a small molecule drug developed by Pfizer. It acts as an antagonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the vanilloid receptor 1. TRPV1 is involved in the detection of noxious chemical and thermal stimuli and plays a role in pain sensation and inflammatory hyperalgesia. By antagonizing TRPV1, PF-3864086 was investigated for its potential to treat pain conditions. The drug has been evaluated in Phase 1 clinical trials for pain but has not advanced beyond this stage[1][2][3].

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on PF-3864086.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-3864086.

Explore the full profile